Sanja Dacic, MD, PhD
Professor of Pathology

Dr. Dacic is a member of the Division of Anatomic Pathology and Director of the FISH and Developmental Laboratory.
Office Location:
Rm. PUH C608
200 Lothrop St.
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-647-8694


  • MD - University of Zagreb, Croatia, 1990
  • PhD - University of Zagreb, Croatia, 1998

2011 Arthur Purdy Stout Society Young Investigator Award

Clinical Expertise

Dr. Dacic is a thoracic surgical pathologist and Director of the FISH and Developmental Laboratory at the University of Pittsburgh Medical Center. Her diagnostic expertise includes neoplastic and non-neoplastic diseases of the lung, and mediastinum and lung transplantation. FISH and Developmental Laboratory offers a large spectrum of FISH and ISH diagnostic and prognostic tests developed under her direct supervision and guideline.

Research Expertise

Dr. Dacic's primary research interests relate to molecular profiling of lung carcinoma and mesotheliomas and detection of biomarkers that have potential to be used clinically for diagnosis, prognostication and treatment of lung carcinoma and mesotheliomas. These interests resulted in numerous invited lectureships and courses in national and international societies and forums. She is a member of the pathology committee for the International Association for Study of Lung Cancer (IASLC) and a member of International Mesothelioma Panel. Dr. Dacic Serves as a Deputy Chief Editor of the Archives of Pathology and Laboratory Medicine. Dr. Dacic is a recipient of Arthur Purdy Stout Prize in 2011 for her research contributions that have had a major impact on diagnostic pathology.

Recent Publications

View Dr. Dacic's publications on PubMed

Schneider F, Luvison A, Cieply K, Dacic S. Sox2 in precursor lesions of lung squamous cell carcinoma. Hum Pathol. 2013 May;44(5):706-11. PMID: 23159246

Yousem SA, Dacic S, Nikiforova M, Nikiforov Y. Pulmonary Langerhans cell histiocytosis:profiling of multifocal tumors using next-generation sequencing identified concordant occurrence of BRAF V600E mutation. Chest. 2013 Jun 1;143(6):1679-84. PMID:23287985

Yousem SA, Lale S, Dacic S. HepPar1 expression in primary lung adenocarcinoma. Am J Clin Pathol. 2013 Aug; 140 (2):225-30. PMID: 23897259

Villaruz LC, Socinski MA, Cunningham DE, Chiosea SI, Burns TF, Siegfried JM, Dacic S. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma Cancer. 2013 Jun 15;119(12):2268-74. PMID:23526491

Tochigi N, Attanoos, Chirieac L, Allen TC, Cagle PT, Dacic S. P16 deletion in sarcomatoid tumors of the lung and pleura. Arch Pathol Lab Med. 2013 May;137(5):632-6. PMID: 23627453

Rodrigues E, Monaco S, Dacic S. Cytological subtyping of lung adenocarcinoma using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification. Cancer Cytopathol. 2013 Aug 13. [Epub ahead of print] PMID:23943235

Lindeman N, Cagle PT, Beasley MB, Chitale D, Dacic S, Giaccone G, Jenkins R, Kwiatkowski D, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors:Guideline from the College of American Pathologists (CAP, International Association for the Study of Lung Cancer (IASLC), Association for Molecular Pathology (AMP).Arch Pathol Clin Med. 2013 Jun;137(6):828-60 PMID:23552377; J Thoracic Oncol. 2013 Jul;8(7):823-59.PMID:23562183; J Mol Diagn 2013 Jul;15(4):415-53PMID:23551194

Strollo DC, Dacic S, Ocak I, Pilewski J, Bermudez C, Crespo MM. Malignancies incidentally detected at lung transplantation: radiologic and pathologic features. AJR Am J Roentgenol. 2013 Jul;201(1):108-16. PMID: 23789663

Bilodeau EA, Weinreb I, Antonescu CR, Zhang L, Dacic S, Muller S, Barker B, Seethala RR. Clear Cell Odontogenic Carcinomas Show EWSR1 Rearrangements: A Novel Finding and a Biological Link to Salivary Clear Cell Carcinomas. Am J Surg Pathol. 2013 Jul;37(7):1001-5. PMID:23715163

Song JY, Siegfried JM, Diergaarde B, Land SR, Bowser R, Stabile LP, Dacic S, Dhir R, Nukui T, Romkes M, Weissfeld JL. Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors. Cancer Epidemiol. 2013 Aug;37(4):518-22. PMID:23619141

Krasinskas AM, Chiosea SI, Pal T, Dacic S. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. Mod Pathol. 2014 Feb;27(2):262-702013 Jul 26. [Epub ahead of print] PMID:23887294

Ramalingam SS, Kotsakis A, Tarhini AA, Heron DE, Smith R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Luketich JD, Belani CP, Argiris A. A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2013 Jul 10. [Epub ahead of print] PMID:23849982

Karunamurthy A, Cai G, Dacic S, Khalbuss WE, Pantanowitz L, Monaco SE. Evaluation of endobronchial ultrasound-guided fine-needle aspirations (EBUS-FNA): correlation with adequacy and histologic follow up. Cancer Cytopathol. 2014 Jan;122(1):23- 32.PMID:24127207

Dacic S, Luvison A, Evdokimova V, Kelly L, Siegfried JM, Villaruz LC, Socinski MA, Nikiforov YE. RET rearrangements in lung adenocarcinoma and radiation. J Thorac Oncol 2014 Jan;9(1):118-20. PMID:24346100

Bastaki JM , Purgina BM, Dacic S, Seethala RR. Secretory myoepithelial carcinoma: a histologic and molecular survey and a proposed nomenclature for mucin producing signet ring tumors. Head Neck Pathol. 2014 Jan 21. PMID:24446021

Li Z, Dacic S, Pantanowitz L, Khalbuss WE, Nikiforova MN, Monaco SE. Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas. Am J Clin Pathol. 2014 Mar;141(3):420-8. PMID:24515771